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It has been established that protein kinase C (PKC) participates in diverse signaling pathways and
cellular functions in a wide variety of cells, exhibiting properties relevant to cellular survival and proliferation.
Currently, however, the regulation mechanism of PKC remains elusive. Here, for the first time, we determine
that phospholipase D2 (PLD2) enhances PKC activity through direct interaction in a lipase activity-inde-
pendent manner. This interaction of the PLD2-Phox homology (PX) domain with the PKC-kinase domain also
induces the activation loop phosphorylation of PKC and downstream signal stimulation, as measured by p70
S6 kinase phosphorylation. Furthermore, only the PLD2-PX domain directly stimulates PKC activity in vitro, and
it is necessary for the formation of the ternary complex with phosphoinositide-dependent kinase 1 and PKC. The
mutant that substitutes the triple lysine residues (Lys101, Lys102, and Lys103) within the PLD2-PX domain with
alanine abolishes interaction with the PKC-kinase domain and activation of PKC. Moreover, breast cancer cell
viability is significantly affected by PLD2 silencing. Taken together, these results suggest that the PLD2-mediated
PKC activation is induced by its PX domain performing both direct activation of PKC and assistance of activation
loop phosphorylation. Furthermore, we find it is an important factor in the survival of breast cancer cells.
Protein kinase C (PKC) has been implicated in many cellular
key functions, such as cell proliferation, survival, and migration
(2, 40, 44). The PKC family is subclassified into three groups—
classical, novel, and atypical PKC—according to differences in
the lipid activation profile (42). It has been established that the
phosphorylation and activation of atypical PKC, especially, is
an important factor in the survival of cancer cells (21, 41). The
phosphorylation of PKC is one of the main mechanisms for
regulating its activity. Recently, it has been reported that mod-
erate activation of PKC is mediated through activation loop
phosphorylation by phosphoinositide-dependent kinase 1
(PDK-1), followed by a subsequent autophosphorylation (8,
38, 59). PKC is also stimulated by the interaction of acidic
lipids, including phosphatidic acid (PA) and phosphoinositides.
Due to its structural uniqueness, PKC is insensitive to second
messengers, such as Ca2 or diacylglycerol (DAG), known to be
potent activators of the other families (46). Therefore, the acti-
vation of PKCmay be expected to rely on a peculiar mechanism,
which is perhaps regulated by many cellular proteins. However,
the exact protein-protein interactions intrinsic to the regulation
mechanism of PKC remain largely unclear.
Phospholipase D (PLD) exists as a membrane-bound pro-
tein and is widely distributed in a variety of cells. It hydrolyzes
phosphatidylcholine to generate choline and PA as a response
to diverse stimuli. In many cancer cells, the abnormal overex-
pression of PLD is associated with the promotion of mitogen-
esis, oncogenic transformation, and cell proliferation and the
suppression of apoptosis (7, 10, 15). PLD activity is most com-
monly controlled by several regulators, such as PKC or small G
protein (ARF, Rho, and RalA), in the presence of phosphati-
dylinositol 4,5-bisphosphate (PIP2) (5, 57, 58, 60). To date, two
phosphatidylcholine-specific mammalian isoforms of PLD,
PLD1 and PLD2, have been isolated and characterized (9, 22,
23). PLD1 is localized mainly in the Golgi apparatus and pe-
rinuclear vesicle regions in multiple cell types (13, 18, 58),
whereas PLD2 is primarily located in the plasma membrane
(12, 19). The differences in the localization of these PLDs can
provide important clues suggesting their specific roles in vari-
ous situations and cell types (12). PLD also has specific do-
mains, such as the Phox (PX) and the pleckstrin homology
(PH) domains. Although it is known that the PX and PH
domains are mediated by protein-protein and protein-lipid in-
teractions, the exact roles of these domains remain unclear and
debatable. Recently, our group had reported that both the
activation and phosphorylation of PLD1 are regulated by
PKC in phorbol myristate acetate-treated COS-7 cells (32)
and that PLD2 activity is also stimulated by PKC in the
neuronal cell (24). Other research had also reported the inter-
relationships between PLD and PKC isoforms in a variety of
cell types (1, 3, 17, 25, 37, 45, 49, 51). So, the regulation
mechanisms of PLD by PKC are relatively well known, but the
details of PKC regulation mechanisms, regarding the PLD, are
still an enigma.
In this study, we determined that PLD2 directly interacts
with PKC, regardless of lipase activity, and suggested that the
PLD2-PX domain can play an important role as an activator of
PKC both through direct stimulation and modulating the ac-
tivation loop phosphorylation of PKC.
MATERIALS AND METHODS
Materials. An enhanced chemiluminescence kit (ECL system) and glutathione
Sepharose 4B were purchased from Amersham Pharmacia Biotech (Bucking-
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hamshire, U.K.). Myelin basic protein and protease inhibitor cocktail were from
Sigma. Rabbit polyclonal anti-phospho Thr410 PKC was kindly provided by
Alex Toker (Harvard Medical School, Boston, Mass.) and purchased from Cell
Signaling (Beverly, Mass.). Anti-actin antibody was from ICN Pharmaceuticals
(Costa Mesa, Calif.). Polyclonal anti-phospho Thr421 and Ser424 p70 S6 kinase
were purchased from Cell Signaling. Rabbit polyclonal PKC was from Santa
Cruz. Anti-PKC and anti-PKC monoclonal antibodies were purchased from
Transduction Laboratories (Lexington, Ky.). Human recombinant PKC, myris-
toylated PKC pseudosubstrate inhibitor, and -octylglucopyranoside were from
Calbiochem (San Diego, Calif.). Human recombinant PKC is phosphorylated at
the threonine 410 residue and has a biologically active ability. Horseradish
peroxidase-conjugated goat anti-rabbit immunoglobulin G (IgG) and goat anti-
mouse IgA, IgM, and IgG were from Kirkegaard & Perry Laboratories (Gaith-
ersburg, Md.). [-32P]ATP and [3H]myristic acid were from Perkin-Elmer Life
Sciences (Boston, Mass.). Immobilized protein A was from Pierce and Dulbec-
co’s modified Eagle’s medium (DMEM) was from Life Technologies, Inc.
(Gaithersburg, Md.). Polyclonal antibody for the recognition of PLD1 and PLD2
was generated as described previously (50).
Purification of recombinant PLD from Sf9 cells. Hexahistidine (His6)-tagged
PLD was expressed in Sf9 cells and purified by chelating Sepharose affinity
column chromatography, as described previously (31).
Cell culture. COS-7 cells were maintained in DMEM supplemented with 10%
(vol/vol) bovine calf serum, at 37°C, in a humidified, CO2-controlled (5%) incu-
bator. HEK (human embryonic kidney 293, MDA-MB 468, and Hs 578T cells
were cultured under the same conditions, but with DMEM containing 10%
(vol/vol) fetal bovine serum. As described previously, these cells were transfected
using Lipofectamine (Life Technologies, Inc.) for the transient expression of the
indicated plasmids and small interfering RNA (siRNA).
siRNA sequences. The siRNA of three independent 21-nucleotide sequences
corresponding to human PLD2 sequences (nucleotides 703 to 723, AAGAGG
UGGCUGGUGGUGAAG; nucleotides 1234 to 1254, AACAGUGGCUAUA
GCAAGAGG; and nucleotides 1966 to 1986, AAGGUGGGCGAUGAGAUU
GUG) and a human PLD1 sequence (nucleotides 1454 to 1474, AAGGUGGG
ACGACAAUGAGCA) were purchased from Dharmacon Research Inc.
(Lafayette, Colo.). The PLD2 siRNA was used in the mixtures of three inde-
pendent sequences for efficient silencing. Results of a BLAST search of all
siRNA sequences revealed no significant homology to any other sequences in the
database program.
Construction and preparation of GST fusion proteins. Glutathione S-trans-
ferase (GST) fusion proteins of PLD2 and PKC were generated as previously
described (30). To further construct the PX and PH domains and F1-1, -2, -3, -4,
-5, -6, and -6M, the N-terminal region (amino acids 1 to 314) of human PLD2 was
used as a template. These mutants of PLD2 were amplified by PCR using specific
primers, digested with restriction enzymes EcoRI and XhoI, and ligated into
pGEX-4T1 vector (Amersham Pharmacia Biotech). PKC deletion mutants such
as F1, F2, F3, and F4, and F3-C1, -C2, -C3, -N1, -N2, -N3, -C2-1, and -C2-2
were also subcloned by the same methods as previously described. Eschericha coli
BL21 cells were transformed with individual expression vectors encoding the
GST fusion proteins and induced with 0.5 mM isopropyl--D-thiogalactopyrano-
side (IPTG) at 25°C for 4 h. After harvesting the cells, GST fusion proteins of
PLD2 and PKC were purified, as previously described. These GST fusion
proteins were purified by standard methods, by using glutathione Sepharose 4B
(30). PLD2-K3A was PCR amplified using forward primer 5-GG GGT ACC
ATG ACG GCG ACC CCT GAG AGC-3, reverse primer 5-TGG ACA ACC
GCG GCG GCA TAC CGT CAT-3, forward primer 5-ATG ACG GTA TGC
CGC CGC GGT TGT CCA-3, and reverse primer 5-GC TCT AGA CTA TGT
CCA CAC TTC TAG GGG-3, digested with restriction enzymes KpnI and
XbaI, and subcloned into mammalian expression vector pcDNA3.1 (Invitrogen,
Carlsbad, Calif.).
Generation of PLD2-WT and PLD2-K3A addback plasmids. One of three
independent 21-nucleotide sequences (siRNA) corresponding to human PLD2
sequences is nucleotides 703 to 723: AAGAGGTGGCTGGTGGTGAAG.
Three residues of human PLD2 cDNA are substituted to AAGAGATGGCTA
GTAGTGAAG for addback mutants of PLD2-WT and -K3A. These mutations
are silencing mutations. This gene is subcloned into mammalian expression
vector pcDNA3.1 (Invitrogen) and digested with restriction enzymes KpnI and
XbaI. These mutations are confirmed through nucleotide sequence analysis.
In vitro binding analysis. In vitro binding between all of the GST fusion
proteins and PLD2 was performed in PLD assay buffer (50 mM HEPES-NaOH,
pH 7.4, 3 mM EGTA, 3 mM CaCl2, 3 mM MgCl2, 80 mM KCl), containing 1%
Triton X-100, 1 mM phenylmethylsulfonyl fluoride, and protease inhibitor cock-
tail, at 4°C for 1.5 h. After a brief centrifugation, the precipitated complexes were
washed three times in the same buffer before being loaded onto a polyacrylamide
gel (30).
Coimmunoprecipitation. COS-7 cells were transfected in combination with the
indicated plasmids. These cultured cells were harvested and lysed with PLD assay
buffer containing 1% Triton X-100, 1% cholic acid, 1 mM phenylmethylsulfonyl
fluoride, and protease inhibitor cocktail. After a brief sonication, the lysates were
centrifuged at 100,000  g for 30 min, and the supernatants (2 mg) were
incubated with anti-PLD or anti-HA antibody-conjugated protein A-Sepharose
for 4 h. After a brief centrifugation, the coimmunoprecipitated complexes were
washed three times with the same buffer before being loaded onto a polyacryl-
amide gel.
Immunoblot analysis. Immunoblot analysis was performed as previously de-
scribed (29). In brief, proteins were denatured by boiling at 95°C for 5 min in a
Laemmli sample buffer. The denatured proteins were then separated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred
to nitrocellulose membranes. After blocking in TTBS buffer (10 mM Tris-HCl,
pH 7.5, 150 mM NaCl, 0.05% Tween 20) containing 5% skimmed milk powder,
the membranes were incubated with individual monoclonal or polyclonal anti-
bodies and subsequently reincubated with either anti-mouse or anti-rabbit IgG,
as required, coupled with horseradish peroxidase. Detection was performed
using an enhanced chemiluminescence kit, according to the manufacturer’s in-
structions. Immunoblot intensity was determined using a Fuji BAS-2000 image
analyzer (Fuji, Tokyo, Japan).
Measurement of PLD activity in cells. PLD activity was assayed by measuring
the formation of phosphatidylbutanol, the product of PLD-mediated transphos-
phatidylation, in the presence of 1-butanol, as previously described (36). In brief,
the cells were labeled with [3H]myristic acid (10 	Ci/ml) for 4 h and then washed
twice with DMEM. The labeled cells were incubated with 0.4% 1-butanol for 5
min, harvested in 0.8 ml of methanol and 1 M NaCl (1:1), and mixed with 0.4 ml
of chloroform. After vortexing, the tubes were centrifuged at 15,000 g for 1
min, the organic phase was dried, and the lipids were separated by a Silica Gel
60 TLC plate, which was then developed with ethyl acetate-trimethylpentane-
acetic acid (9/5/2, vol/vol/vol). The amount of [3H]phosphatidylbutanol formed
was expressed as a percentage of the total 3H-lipid, to account for differences in
cell labeling efficiency.
PKC kinase assay. PKC activity was measured by the aforementioned pro-
tocol, with minor modifications (6). In brief, PKC was incubated with myelin
basic protein (2 	g) at 37°C for 30 min in kinase buffer (50 mM Tris-HCl, pH 7.5,
100 	M Na3VO4, 100 	M Na4P2O7, 1 mM NaF, 100 	M phenylmethylsulfonyl
fluoride, 4 	g of phosphatidylserine, 5 mM MgCl2, 10 	Ci of [-32P]ATP [3,000
Ci/mmol]), and an in vitro phosphorylation assay was performed. This reaction
was terminated by the addition of 15 	l of 2 SDS sample buffer and boiling of
the samples for 5 min. The sample was analyzed by SDS-PAGE and exposed to
photographic film for autoradiography.
MTT assay in the breast cancer cells. The MTT assay was used as a crude
measurement of cell viability (16). MTT is a yellow tetrazolium [3-(4,5-dimeth-
ylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] which is converted by metabol-
ically active cells into a colored water-insoluble formazan salt. The cells were
seeded at 5  104/ml (100 	l/well) in 96-well plates, grown for 36 h, and depleted
with serum for indicated times. MTT reagent (5 mg/ml in phosphate-buffered
saline) was then added to the cells (10 	l/well), and the cultures were incubated
at 37°C for 2 h. The reaction was stopped by the addition of 70 	l of isopropanol
(including 0.2% HCl), and the tetrazolium crystals were dissolved at room
temperature. The samples were measured by a Biotrak II Reader at a test
wavelength of 450 nm.
RESULTS
PKC interacts with PLD2. Our group had previously pub-
lished results suggesting that the activation and phosphoryla-
tion of PLD1 are regulated by PKC in phorbol myristate
acetate-treated COS-7 cells (32) and that PLD2 activity is also
controlled by PKC in PC12 cells (24). To delineate the spec-
ificity of interactions between PLD2 and PKC isozymes, we
attempted to examine the physical associations between PLD2
and PKC isozymes in COS-7 cells. As shown in Fig. 1A, we
observed that three PKC isozymes, PKC, -, and -, interact
with PLD2 in a fashion similar to their respective interaction
potencies. Furthermore, PLD2 activity is upregulated by
PKC- or PKC-overexpressed cells, but its activity is unaf-
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fected by PKC in the same cells (Fig. 1B). We also obtained
similar results in HEK 293 cells (data not shown). These re-
sults demonstrated that PLD2 associates with PKC, resulting
in the formation of a physical complex.
PLD2 specifically interacts with PKC in a lipase activity-
independent manner. In the next phase of the experiment, we
further confirmed the specificity of PLD isozymes on PKC
binding. As shown in Fig. 2A, PLD2, rather than PLD1,
FIG. 1. The effects of representative PKC isoforms, including , , and , on PLD2 interaction and activity. COS-7 cells transiently transfected with
indicated constructs were cultured for 36 h. A. The cells were lysed with buffer containing 1% Triton X-100 and 1% cholic acid. The extracts were
immunoprecipitated (I.P.) with anti-PLD antibody. After a brief centrifugation and washing, the precipitates were subjected to SDS-PAGE and
immunoblotted with anti-PLD2 and anti-PKC, -, and - antibodies. B. The cells were labeled with [3H]myristic acid for 4 h. The measurement of
[3H]phosphatidylbutanol formation was quantified as described in Materials and Methods. The data represent one of two independent experiments.
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FIG. 2. The effects of PLD isozymes and lipase activity on PKC interaction. A. COS-7 cells transiently transfected with indicated constructs
were grown for 36 h. The cell lysates were solubilized with buffer containing 1% Triton X-100 and 1% cholic acid. The extracts were immuno-
precipitated (I.P.) with anti-PLD antibody or antihemagglutinin (HA) antibody. The complexes were briefly washed with the same buffer, subjected
to SDS-PAGE, and immunoblot analyzed with anti-PLD antibody and anti-HA antibody. B. COS-7 cells were transfected with indicated plasmids,
cultured, and harvested with lysis buffer. The extracts were immunoprecipitated with anti-PLD antibody, and the precipitates were subjected to
immunoblot analysis with the indicated antibodies. C. COS-7 cells (2 mg) growing in media supplemented with 10% bovine calf serum were lysed
with buffer containing 1% Triton X-100 and 1% cholic acid. Immunoprecipitation with the indicated antibodies was performed as described in
Material and Methods and 40 	g of cell lysate was loaded for the total lysate blot.
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strongly interacts with PKC. To investigate the involvement of
PLD lipase activity in the interactions between proteins, we
transfected the indicated cDNA encoding plasmids in COS-7
cells. As shown in Fig. 2B, the PLD2 lipase inactive mutant
(PLD2-K758R) as well as the PLD2 wild type (PLD2-WT)
interact with PKC, regardless of lipase activity. Furthermore,
as shown in Fig. 2C, we also determined that endogenous
PLD2 as a major isoform in COS-7 cells is coimmunoprecipi-
tated with endogenous PKC. These results demonstrated that
the specific interaction between PLD2 and PKC occurs in a
lipase activity-independent manner.
The triple lysine residues within the PLD2-PX domain are
required for interaction with PKC. We also confirmed that
the purified PLD2 directly interacts with PKC in vitro (data
not shown). To determine the PKC-binding region in PLD2,
we generated GST fusion fragments of PLD2. The schematic
diagram and the individual GST fusion fragments of PLD2
used in this study are depicted in Fig. 3A. We performed in
vitro binding analysis with GST fusion fragments of PLD2. The
N-terminal region (amino acids 1 to 314) of PLD2 is required
for binding to PKC (Fig. 3B). In the N-terminal region, the
PX domain is necessary for interaction with PKC (Fig. 3C).
FIG. 3. The requirement of the triple lysine residues within the PLD2-PX domain for PKC interaction. A. Primary structure and individual
domains of PLD2 used in this study. GST fusion proteins containing individual different domains of PLD2 were expressed in bacteria and purified
by glutathione Sepharose beads. The individual fragments of PLD2 were followed by F1 (amino acids [a.a.] 1 to 314), F2 (a.a. 315 to 475), F3 (a.a.
476 to 612), F4 (a.a. 613 to 723), F5 (a.a. 724 to 825), F6 (a.a. 826 to 934), PX domain (a.a. 65 to 192), and PH domain (a.a. 201 to 310). F1-1
(a.a. 1 to 67), F1-2 (a.a. 1 to 113), F1-3 (a.a. 1 to 166), F1-4 (a.a. 66 to 112), F1-5 (a.a. 66 to 88), F1-6 (a.a. 88 to 112), and F1-6M (a.a. 88 to 112;
K101/102/103A). B, C, D, and E. GST fusion proteins containing individual fragments of PLD2 were incubated with COS-7 cell lysates as a source
of PKC for 1.5 h. After brief centrifugation and washing, the precipitates were subjected to SDS-PAGE and analyzed with anti-PKC antibody.
The details of the experiment are described in Materials and Methods. The total amount of GST fusion proteins used in this experiment was shown
by Ponceau S staining. I.B., immunoblot.
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We generated serial deletion mutants of the PX domain to do
fine mapping of the binding site. It is critical for the amino acid
68 to 113 region derived from serial deletion mutants of the
PLD2-PX domain and, especially, for the amino acid 88 to 112
region to interact with PKC. This was verified through de-
tailed binding analysis (Fig. 3D and E). It has been reported
that the positive- or negative-charge residues of PKC inter-
acting proteins are important for the associations between both
proteins (43, 53). On the basis of previous reports, we gener-
ated a mutant in the triple lysine residues (Lys101, Lys102, and
Lys103) within the PLD2-PX domain and also confirmed that
these residues are critical in the interaction with PKC (Fig.
3E). Furthermore, we generated a PLD2 mutant, in which the
triple lysine residues were substituted with alanine (PLD2-
K101/102/103A; PLD2-K3A). Coimmunoprecipitation binding
analysis showed that the PLD2-K3A mutant abolishes interac-
tion with endogenous PKC in COS-7 cells (see Fig. S1 in the
supplemental material). Taken together, these results led us to
the conclusion that the triple lysine residues within the
PLD2-PX domain are responsible for association with PKC.
The PKC-kinase domain is responsible for direct interac-
tion with PLD2. PKC is comprised of three distinctive do-
mains, including Phox and Bem1p (PB1), C1, and the serine/
threonine kinase domains. The GST fusion fragments of PKC
used in this study are shown in Fig. 4A. We prepared GST
fusion fragments of PKC and performed GST pull-down as-
says. As shown in Fig. 4B, the PKC-kinase domain interacts
exclusively with PLD2 purified from Sf9 cells and not with the
PB1 and C1 domains. To specifically verify the potential inter-
action region, we generated serial deletion mutants of the
PKC-kinase domain and carried out GST pull-down assays.
As shown in Fig. 4C and D, the amino acid 348 to 370 region
within the PKC-kinase domain is responsible for interaction
with PLD2. Taken together, these results suggest that the
amino acid 348 to 370 region within the PKC-kinase domain
is required for binding to PLD2.
FIG. 3—Continued.
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FIG. 4. The interaction of PLD2 with the amino acid 348 to 370 region within the PKC-kinase domain. A. Primary structure and individual
domains of PKC used in this study. GST fusion proteins containing distinctive domains of PKC were expressed in E. coli and purified by
glutathione Sepharose beads. The individual fragments of PKC were followed by F1 (amino acids [a.a.] 1 to 98), F2 (a.a. 99 to 251), F3 (a.a.
252 to 519), F4 (a.a. 520 to 592), F3-C1 (a.a. 252 to 460), F3-C2 (a.a. 252 to 390), F3-C3 (a.a. 252 to 320), F3-N1 (a.a. 320 to 519), F3-N2
(a.a. 390 to 519), F3-N3 (a.a. 460 to 519), F3-C2-1 (a.a. 252 to 370), and F3-C2-2 (a.a 252 to 347). B, C, and D. GST fusion proteins containing
PKC fragments were incubated with recombinant PLD2 purified from Sf9 cells. After brief centrifugation and washing, glutathione bead
complexes were subjected to SDS-PAGE and analyzed by immunoblotting (I.B.) with anti-PLD2 antibody. The total amount of GST fusion
proteins used in this experiment was shown by Ponceau S staining.
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The F1-6 fragment directly stimulates PKC activity in
vitro. Considering the findings that the triple lysine residues
within the PLD2-PX domain directly interact with the PKC-
kinase domain (Fig. 3 and 4), we examined the kinase activity
of PKC to substantially characterize the meaning of the in-
teractions between the two proteins. We performed in vitro
phosphorylation assays with maltose binding protein (MBP)
and phosphorylated PKC. As shown in Fig. 5, the F1-4 frag-
ment corresponding to the amino acid 66 to 112 region within
the PLD2-PX domain exhibits an approximate 10-fold increase
in autophosphorylation and displays an approximate eightfold
increase in MBP phosphorylation and, interestingly, the F1-6
fragment corresponding to the amino acid 88 to 112 region
induces about a sixfold increase in PKC activity. However, the
F1-5 and F1-6M fragments, which are deficient in binding
ability, result in a little less than a twofold increase in PKC
activity. The obvious conclusion is that PKC activity is more
efficiently stimulated by F1-6 than by F1-6M. These results
suggest that the amino acid 88 to 112 region within the
PLD2-PX domain has the ability to directly stimulate PKC
activity.
PLD2 protein significantly stimulates PKC activity in cells.
Because the PLD2-PX domain can directly stimulate PKC
activity in vitro (Fig. 5), we attempted to verify whether the
PLD2-mediated PKC activation induces the propagation of
downstream signaling flow in cells. It has been reported that
PKC induces p70 S6 kinase activation in murine prostate
cancer cells such as TRAMP (21). Actually we observed that
activation of p70 S6 kinase is potentiated in PKC-WT adeno-
virus-infected COS-7 cells and decreased in PKC-DN-ex-
pressing cells under similar conditions without changing the
PLD2 expression (see Fig. S2 in the supplemental material).
FIG. 5. The effects of the specific binding motif within the PLD2-PX domain on PKC activity. The activation loop-phosphorylated PKC was
incubated with specific fragments within the PLD2-PX domain, such as F1-4, F1-5, F1-6, and F1-6M in kinase buffer (50 mM Tris-HCl, pH 7.5,
100 	M Na3VO4, 100 	M Na4P2O7, 1 mM NaF, 100 	M phenylmethylsulfonyl fluoride, 4 	g of phosphatidylserine, 5 mM MgCl2, 10 	Ci of
[-32P]ATP [3,000 Ci/mmol]) for 30 min, and an in vitro phosphorylation assay was performed. This reaction was terminated by the addition of
SDS sample buffer, and the precipitates were subjected to SDS-PAGE and exposed to photographic film for autoradiography. The data represent
one of three independent experiments. The detailed procedures are described in Materials and Methods.
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As shown in Fig. 6A, the activation of p70 S6 kinase is en-
hanced in PLD2-WT- and PLD2-K758R-overexpressed COS-7
cells, but PLD2-K3A had no effect on p70 S6 kinase activation
in comparison with vector-transfected cells. Furthermore,
when endogenous PLD2 is depleted by siRNA, the activation
of p70 S6 kinase is lessened in comparison with that of control
siRNA for luciferase (Fig. 6B). Interestingly, as shown in Fig.
6A, we observed that the activation loop phosphorylation
(pT410) of endogenous PKC was significantly enhanced in
PLD2-WT and -K758R cells but not PLD2-K3A-transfected
cells. When endogenous PLD2 expression was silenced with
PLD2 siRNA, the activation loop phosphorylation of PKC
decreased dramatically (Fig. 6B). Taken together, these results
suggest that the activation and phosphorylation of PKC might
be regulated by PLD2 protein, in a correlative fashion with p70
S6 kinase activation.
The ternary complex including PDK-1, PLD2, and PKC is
formed in COS-7 cells. Because the activity of PDK-1 phos-
phorylating Akt has been unaffected by the extent of PLD2
expression, indicating that PLD2 may not directly affect PDK-1
activity (see Fig. S3 in the supplemental material), we exam-
ined whether PLD2 exists in the physical complex of PDK-1
and PKC, hence increasing the activation loop phosphoryla-
tion of PKC. As shown in Fig. 7A, PLD2-K758R as well as
PLD2-WT existed in the ternary complex with PDK-1 and
PKC. However, PLD2-K3A did not exist in this complex.
PLD2-K3A bound with PDK-1 but not PKC, and PLD2-K3A
had no effect on the complex arising from the interaction of
PKC with PDK-1. Since the PLD2-PX domain was involved in
direct interaction with PKC (Fig. 3C), we examined whether
it was sufficient for ternary complex formation and enhanced
activation loop phosphorylation of PKC. As shown in the Fig.
7B, surprisingly, the PLD2-PX domain was found to exist in a
physical complex with PKC and PDK-1 and to enhance acti-
vation loop phosphorylation of PKC. But the PLD2-PX-K3A
domain did not form the physical ternary complex with PKC
and PDK-1 and had no effect on binding of PKC to PDK-1.
Taken together, these results suggested that the PLD2-PX
domain also plays the role of a critical cofactor, helping the
activation loop phosphorylation of PKC in a ternary complex
with PKC and PDK-1.
Cell viability is affected by PLD2 silencing in breast cancer
cells. Recent reports have demonstrated that the regulation of
PKC activity is relevant to cell survival and apoptosis in breast
cancer cells (41) and also that PLD2 is highly overexpressed in
a wide variety of human cancer cells (48, 60, 61, 63). Therefore,
we examined whether the activation of PKC is controlled by
PLD2 expression. In Fig. 8A and B, we demonstrated that
activation loop phosphorylation and activity of PKC de-
creased dramatically under PLD2 silencing conditions in
breast cancer cells containing Hs 578T and MDA-MB 468
cells. The activation of p70 S6 kinase also significantly de-
creased under the same circumstances with a concomitant cor-
relation with the attenuation of PKC activation loop phos-
phorylation. The PDK-1 activity was unaffected by PLD
silencing in breast cancer cells (see Fig. S4 in the supplemental
material). As shown in Fig. 8C and D, cell viability is attenu-
ated in PLD2-silenced breast cancer cells with a correlation to
cells treated with PKC inhibitors in a time-dependent man-
ner. Control and PLD1-silenced cells exhibited significantly
less effects on cell viability than did PLD2-silenced cells. Fur-
thermore, as shown in Fig. 8E and F, it was also determined
that the cell viability was recovered by PLD2-WT (addback
plasmids) and PLD2-WT-PX but not by PLD2-K3A (addback
FIG. 6. The effects of PLD protein on activation of PKC and
p70S6K. A and B. COS-7 cells were transfected with the indicated plas-
mids encoding various PLD2 constructs or siRNA for control (luciferase)
and PLD2, cultured for 36 h, starved in serum for 12 h, and then lysed with
buffer containing 0.1% Triton X-100 for 30 min on ice. The cell lysates,
removed from the crude nuclear fraction using centrifugation, were ana-
lyzed by immunoblotting with indicated antibodies. The n-fold increase is
expressed as the percentage of the indicated antibodies’ intensity above
the basal level. Results are expressed as average values 
 standard errors
of three independent experiments. *, P of 0.05 compared with vector
(Vec) or control (Con) siRNA-transfected cells.
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FIG. 7. The formation of ternary complex including PDK-1, PLD2, and PKC. A. COS-7 cells were transiently transfected with various PLD2
constructs, grown for 48 h, depleted with serum for 12 h, and then lysed with buffer containing 1% Triton X-100 and 1% cholic acid. The extracts,
immunoprecipitated (I.P.) with anti-PLD antibody or antihemagglutinin (HA) antibody, were analyzed by immunoblotting with indicated
antibodies. Anti-actin antibody was used with normalized control. B. COS-7 cells were transfected with the indicated plasmids encoding vector
(Vec), Flag-tagged PLD2-PX-WT, and Flag-tagged PLD2-PX-K3A, cultured for 36 h, depleted with serum for 12 h, and then lysed with buffer
containing 0.1% Triton X-100 for 30 min on ice. The cell lysates, removed from the crude nuclear fraction using centrifugation, were immuno-
precipitated with anti-Flag antibody. The precipitated complex was analyzed with the indicated antibodies. The total lysates were also analyzed by
immunoblotting with the indicated antibodies. The n-fold increase is expressed as a percentage of the indicated antibodies’ intensity above the basal
level. The experiment represents one of three independent experiments. *, P of 0.05 compared with vector-transfected cells.
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FIG. 8. The effects of PLD silencing on cell viability in breast cancer cells. A and B. Hs 578T cells and MDA-MB 468 cells were transfected with
siRNA for control (Con), PLD1, and PLD2. The details of the procedures are described in Materials and Methods. In brief, the cells were cultured for
48 h, depleted with serum for 12 h, and then lysed with buffer containing 0.1% Triton X-100, for 30 min on ice. The cell lysates, removed from the crude
nuclear fraction by using centrifugation, were analyzed by immunoblotting with the indicated antibodies. The n-fold increase is expressed as the
percentage of the indicated antibodies’ intensity above the basal level. The data represent one of three independent experiments. *, P of0.05 compared
with control siRNA-transfected cells. C and D. Hs 578T cells and MDA-MB 468 cells were transfected with siRNA for control, PLD2, and PLD1 and
treated with the myristoylated PKC pseudosubstrate inhibitor (50 	M). After serum depletion for the indicated time points, the cells were washed, lysed
with isopropanol including 0.2% HCl, and measured at a wavelength of 450 nm. *, P of 0.05 compared with control siRNA-transfected cells; † or ‡,
P of 0.05 versus PLD2 or PLD1 siRNA-transfected cells; ¦, P of 0.05 versus PKC inhibitor-treated cells. E and F. Hs 578T (panel E) and MDA-MB
468 (panel F) cells were transfected with the indicated siRNA and plasmids. The siRNA used in the experiments was nucleotides 703 to 723,
AAGAGGTGGCTGGTGGTGAAG, for addback of PLD2-WT or -K3A (addback plasmids). After serum depletion for 48 h, the cells were washed,
lysed with isopropanol including 0.2% HCl, and measured at a wavelength of 450 nm. *, P of 0.05 compared with control siRNA-transfected cells; †,
P of 0.05 versus PLD2 siRNA-transfected cells; ‡, P of 0.05 versus PLD2 siRNA  PLD2-WT addback; ¦, P of 0.05 versus PLD2 siRNA 
PLD2-K3A addback; ¶, P of 0.05 versus PLD2 siRNA  PLD2-WT-PX; §, P of 0.05 versus PLD2 siRNA  PLD2-K3A-PX.
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plasmids) and PLD2-K3A-PX. These results suggest that
PLD2-mediated PKC activation is important for the survival
of breast cancer cells.
DISCUSSION
PLD has a large role in the activity of lipid hydrolysis, and
until now there have been many reports that its activity is
elaborately controlled by many cellular regulators in diverse
cell systems (20, 22, 26, 31, 33, 34, 35, 37, 50). In contrast, little
is known about the details of mechanisms in the regulation of
other proteins by PLD through direct binding. In this study, we
suggest that the PLD2-PX domain directly binds to PKC,
simultaneously performing dual roles—one as a direct activa-
tor for PKC, and the other as a cofactor increasing the acti-
vation loop phosphorylation of PKC (Fig. 9). Furthermore,
PLD2-mediated PKC activation is also implicated in cancer
cell viability.
The conventional PKC activation mechanisms are well un-
derstood. Mechanisms have been established for sequential
phosphorylation, the recruiting of proper localization, and the
exchanging of binding proteins (47). It is generally understood
that synthesized PKC is translocated into the membrane and
phosphorylated by PDK-1 and that phosphorylated PKC is
regulated by Ca2 or DAG generated by stimuli, culminating
in the release of specific domains from the substrate binding
cavity (61). In contrast, since PKC is insensitive to second
messengers such as Ca2 and DAG in its PB1 and C1 domains,
it has been theorized that its activity is primarily regulated by
protein-protein interaction. However, the activation mecha-
nisms and cellular regulators of PKC remain unclear. Here,
our data demonstrated that, regardless of lipase activity, PLD2
enhances the activation of PKC by increasing the activation
loop phosphorylation of PKC under basal conditions. Also,
the activation loop-phosphorylated PKC is stimulated by di-
rect binding of PLD2 (Fig. 5). Moreover, PLD2-mediated
PKC activation induces the phosphorylation of p70 S6 kinase,
resulting in downstream signal flow (Fig. 6). The regulation of
PKC activity by PLD2 results from the signaling complex
composed of PDK-1 and PKC, not from the upregulation of
PDK-1 activity as upstream kinase (Fig. 7A; also see Fig. S3 in
the supplemental material). Furthermore, PLD2-WT, like
PLD2-K3A, has no effect on binding with PDK-1 or on the
binding of PKC with PDK-1. According to previous reports,
when PKC is translocated into the membrane, bound to
PDK-1, and then phosphorylated, PLD2 as a membrane-
bound protein can assist the activation loop phosphorylation of
PKC (Fig. 6). In this study, we suggest PLD2 as a novel
protein cofactor for full and complete activation of PKC.
PKC phosphorylates p70 S6 kinase. Furthermore, it is
known that p70 S6 kinase is activated through multiple-site
phosphorylation. Another kinase for p70 S6 kinase is known to
be mTOR, which is rapamycin sensitive and a target of PA (4,
14). mTOR phosphorylates p70 S6 kinase at the Thr389 residue
in a PA-dependent manner, but PKC phosphorylates p70 S6
kinase at the Thr421 and Ser424 residues regardless of PA
because, as shown in Fig. 6A, the PLD2-K758R lipase-inactive
mutant abolishes generation of PA and also PLD2-WT in-
FIG. 8—Continued.
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creases phosphorylation of p70 S6 kinase. So, PLD2 interac-
tion-dependent PKC activation could stimulate p70 S6 kinase.
Accordingly, p70 S6 kinase activation is differently regulated by
two kinases such as PKC and mTOR. Moreover, PLD2-me-
diated PKC, rather than mTOR activated by PA, phosphor-
ylates p70 S6 kinase at the Thr421 and Ser424 residues.
PKC activity is regulated by dual mechanisms—the direct
activation of PLD2 in vitro and assistance of the activation
loop phosphorylation of PKC (Fig. 5 and 6). PLD2 stimulates
PKC activity through direct interaction with the PKC-kinase
domain (Fig. 4). The distinctive domains of PKC, including
PB1, C1, and the kinase domain, are known to mediate pro-
tein-protein or protein-lipid interactions. It is known that the
specific domains of PKC are important for interacting with
several binding proteins such as Par6, Par3/ASIP, Cdc42, and
mammalian Lgl, involved in cell polarity (28, 39, 52), and
p62/ZIP, MEK5, and p70 S6 kinase, implicated in the signal
transduction pathway (11, 52, 54, 56). Among the interacting
proteins, Par3 exhibits the greatest affinity for the kinase do-
main, but whether its interaction regulates kinase activity re-
mains unclear (39). In this study, we determine that PLD2
interacts with the amino acid 348 to 370 region within the
PKC-kinase domain, subsequently regulating PKC activity.
A recent report has predicted this region, by multiple sequence
alignment under secondary structure modeling, to be located
in the -E helix within the C-lobe side of the kinase domain
(64). In the case of cyclin-dependent kinase (CDK), the acti-
vation loop has been found to be structurally coupled with the
-C helix, stabilizing its inactive conformation. The direct in-
teraction of cyclin with the -C helix of CDK induces an
alteration in the orientation of the -C helix and eventually
results in activation loop phosphorylation by CDK-activating
kinase (27, 55). We suggested that PLD2, interacting with the
amino acid 348 to 370 region corresponding to the -E helix,
can facilitate activation loop phosphorylation, due to a confor-
mational change of PKC by interactions with the neighboring
phosphorylation site. This region can also hold the possible
potential motif providing the direct binding site for the
PLD2-PX domain, necessary for the full activation of PKC.
Surprisingly, the PLD2-PX domain is only sufficient for the
signaling complex with PKC and PDK-1 and enhances the
activation loop phosphorylation of PKC (Fig. 7B). The
PLD2-PX domain also contains an activation motif of PKC,
indicating the stimulation of activation loop-phosphorylated
PKC activity through direct interaction. The autophosphory-
lation of PKC was also enhanced by the PLD2-PX domain
and then activated PKC increased the phosphorylation of
MBP (Fig. 5). Therefore, we suggest that PKC activation by
PLD2 binding may be a new mechanism for kinase activation.
Furthermore, as shown in Fig. S6 in the supplemental material,
it is suggested that PKC phosphorylation is attenuated under
the basal condition in PLD2-silenced cells, and the signal-
dependent PKC phosphorylation also is decreased in PLD2-
silenced cells. In addition, the signal-dependent PKC phos-
phorylation occurs as the basal PKC phosphorylation is
reduced by PLD2 silencing. Therefore, it was found that PLD2
is essential for basal PKC activation. The issue of PLD2-PKC
signaling may require further characterization.
PLD2 has two distinctive domains including the PX and PH
domains. Their exact roles have not yet been well defined.
Recently, our group suggested that one of the roles of the
PLD2-PX domain is the exertion of an anchoring function,
supporting the thesis that PLD2 functions as an adaptor in the
redistribution of PLC-1 to the membrane region in epidermal
growth factor signaling (26). We also theorized that it may play
a secondary role, in the provision of the docking sites regulat-
FIG. 9. Proposed model of PKC activation by PLD2. The PLD2-PX domain directly interacts with the PKC-kinase domain. Ultimately, PLD2
is a ternary complex of PKC with PDK-1 and its PX domain assists the activation loop phosphorylation of PKC by PDK-1. The activation
loop-phosphorylated PKC is fully stimulated through direct interaction of PLD2-PX domain. The completely activated PKC (black) upregulates
downstream signals, such as p70 S6 kinase.
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ing PLD2 activity with its interacting protein, such as
Munc18-1 (33). Here, we suggest that another of its functions
is to serve as a novel direct activator for PKC, since the
PLD2-PX domain can enhance stimulation and activation loop
phosphorylation of PKC (Fig. 5 and 7B). The triple lysine
residues within the PLD2-PX domain are especially responsi-
ble for PKC activation and interaction. However, the PLD2-
K3A mutant abolishes interactions with PKC and inhibits its
mediated PKC activation (Fig. 3 and 5). Although it cannot be
affirmed that these mutations have no effects on the confor-
mation of the PLD2-PX domain, it does not change the ex-
pression level, subcellular localization, or catalytic properties
of PLD2 in vitro (data not shown). These results suggest that
the effect of these mutations on PLD2 structure, if any, is
neither dramatic nor significant in PLD2 function, except for
its interaction with PKC. Taken together, we suggest that the
PLD2-PX domain, as one of a collection of multiple binding
modules, executes a myriad of functional roles in various cel-
lular contexts.
PLD2 is known to be highly overexpressed in a wide variety
of human cancer cells (48, 62, 63, 65), but it is unclear what the
role of PLD might be in cancer cells. Furthermore, there are
several reports in which the regulation of PKC, and p70 S6
kinase activity, is implicated in cell survival and apoptosis in
prostate and breast cancer cells (21, 41). As shown in Fig. 8, we
determined that the PLD2-mediated PKC activation is im-
portant for cell viability after the induction of cell death as a
serum-depleted condition. Furthermore, we demonstrated that
the effects of PLD2 silencing on the viability of breast cancer
cells are nonadditive in PKC inhibitor-treated cells for sup-
porting functional significance (see Fig. S5A and B in the
supplemental material). We performed PKC rescue experi-
ments to reveal the linking between PLD2 and PKC after
silencing with PLD2 siRNA (see Fig. S5C and D in the sup-
plemental material). As the amounts of PKC were increased,
the cell viability was not significantly rescued under the PLD2
silencing condition. The reason that cell survival was not com-
pletely recovered is possibly the result of the silencing of
PLD2, which acts as either a cofactor or activator for PKC.
Therefore, PKC activation is dependent on PLD2 signaling.
Therefore, we suggested that PLD2-mediated PKC activation
is essential for the survival of breast cancer cells. Considering
whether these tumor cells, if any, exist in either serum-ex-
hausted or nutrient-deficient conditions in the angiogenesis
process, we suggested that the PLD2-mediated PKC activa-
tion may be important in the survival of breast cancer cells.
Accordingly, the issue of physical interaction may be applied to
unravel some problems in cancer cells and necessary to further
characterize the uncertain details of the signal mechanisms.
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